An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B

Published: 25-01-2011
Last updated: 27-04-2024

Primary Objective: To evaluate the haemostatic effect of N9-GP during surgery procedures in patients with haemophilia B.Key Secondary Objectives• To evaluate the haemostatic effect of N9-GP during surgery and the postoperative period.• To evaluate...

Ethical review	Approved WMO
Status	Will not start
Health condition type	Coagulopathies and bleeding diatheses (excl thrombocytopenic)
Study type	Interventional

Summary

ID

NL-OMON36798

Source
ToetsingOnline

Brief title
Paradigm3

Condition

- Coagulopathies and bleeding diatheses (excl thrombocytopenic)

Synonym
blood clotting disorder, Haemophilia B

Research involving
Human

Sponsors and support

Primary sponsor: Novo Nordisk
Source(s) of monetary or material Support: Novo Nordisk (industrie)

Intervention

Keyword: Haemophilia B, N9-GP, Surgery, Trial

Outcome measures

Primary outcome

Primary Endpoint: Haemostatic effect during surgery evaluated by a four-point response scale (Excellent, good, moderate poor), assessed by the Investigator/Surgeon at the day of surgery

Secondary outcome

Key Secondary Endpoints:

• Consumption of N9-GP (U/kg Body Weight) during surgery and post-operative period

• Transfusion requirements during surgery and the post-operative period

• Haemoglobin pre and post surgery start (0, 1 h, 24 h and every 24 hours in the post-operative period)

• AE and SAEs reported during the trial period until the last visit

• Incidence of inhibitors against FIX (>=0.6 BU) until the last visit

Study description

Background summary

The rationale for this trial is to investigate efficacy and safety of N9-GP during surgery in haemophilia B patients. A surgery trial is in accordance with the draft European Medicines Agency (EMA) guideline on clinical investigation

of recombinant and human plasma-derived Factor IX products. The trial will provide information on the bleeding-preventive effect during surgery, the bleeding-arresting haemostatic effect during and after these procedures and the safety profile of N9-GP in patients with haemophilia B. Based on clinical and non-clinical studies conducted, N9-GP is a promising drug candidate for prevention/prophylaxis and on-demand treatment of bleedings in haemophilia B patients. The completed phase 1 trial showed a mean t* of 93 hours which is approximately 5 times higher than commercially available FIX concentrates.

Study objective

Primary Objective: To evaluate the haemostatic effect of N9-GP during surgery procedures in patients with haemophilia B.

Key Secondary Objectives
• To evaluate the haemostatic effect of N9-GP during surgery and the postoperative period.
• To evaluate the general safety, including immunogenicity of N9-GP, when used for prevention and treatment of bleeding during surgery and the post-operative period.

Study design

The design is open-label, multi-centre, un-controlled, efficacy and safety trial evaluating N9-GP in minimum 10 major surgeries in 5-10 patients.

This trial will provide information on the bleeding-preventive efficacy and safety profile of N9-GP when administered before, during and after surgery.

Patients enrolled in this trial can be recruited from the pivotal trial (Paradigm2) or the extension trial (Paradigm4). In addition, new patients can also be recruited into the present trial. Patients will be offered to continue on prophylactic treatment or on-demand treatment in the extension trial (Paradigm4).

The trial will consist of a Screening visit (for new patients) or a Pre-surgery visit (for patients transferred from the pivotal trial (Paradigm2) and the extension trial (Paradigm4)), Day of surgery (Visit 2), and a post-operative period (Day 1-13; Visit 3).

Intervention

Weekly injections with N9-GP in the period prior to the surgery.
An initial injection with N9-GP on the day of surgery, and afterwards depending on the patients needs.

Besides, surgery related interventions.

Study burden and risks

It's possible that bloodwithdrawals or injections with N9-GP can cause haemorrhages or discomfort. There is also a very small chance of infection on the injection site. The patient could also experience side effects from N9-GP. There is a risk of development of antibodies against N9-GP and/or FIX that could decrease the effectiveness of future treatments with FIX products.

Contacts

Public
Novo Nordisk

Flemingweg 18
2408 AV Alphen a/d Rijn
NL
Scientific
Novo Nordisk

Flemingweg 18
2408 AV Alphen a/d Rijn
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

• Male patients, aged 13-70 years, with moderately severe or severe congenital haemophilia B with a FIX activity <=2% according to medical records
NB: In The Netherlands only patients aged 18-70 years will be included
• History of at least 150 exposure days to other FIX products
• Scheduled major surgery

Exclusion criteria

• Known history of FIX inhibitors based on existing medical records, laboratory report reviews and patient and LAR interviews
• Current FIX inhibitors >=0.6 BU (central laboratory)
• Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)
• ALT >3 times the upper limit of normal reference ranges at screening (central laboratory)
• Immune modulating or chemotherapeutic medication

Study design

Design

Study phase:	3
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Will not start
Enrollment:	2
Type:	Anticipated

Medical products/devices used

Product type:	Medicine
Brand name:	Not yet known
Generic name:	N9-GP

Ethics review

Approved WMO Date:	25-01-2011
Application type:	First submission
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)
Approved WMO Date:	24-08-2011
Application type:	First submission
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)
Approved WMO Date:	12-09-2011
Application type:	Amendment
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)
Approved WMO Date:	16-01-2012
Application type:	Amendment
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)
Approved WMO Date:	13-02-2012
Application type:	Amendment
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)
Approved WMO Date:	17-04-2012
Application type:	Amendment
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)
Approved WMO Date:	15-01-2014
Application type:	Amendment
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2010-023070-40-NL
ClinicalTrials.gov	NCT01386528
CCMO	NL35219.041.11